[Ip-health] US-India Business Council and 3d report

[Asia Russell]

Does anyone know more about this "USIBC Synergies Summit" today in
Washington, where a report on 3d will be released? Is anyone planning
to attend?

The article claims Minister of Commerce from India apparently will
attend, along with USTR Ron Kirk.



Thanks

Asia

> New study on protecting new drugs in India
>
> Washington (IANS): 17 June, A major new study identifying a broad
> range of potential benefits of incremental pharmaceutical innovation
> for India will be released at the US-India Business Council's
> (USIBC) Synergies Summit here Wednesday.
>
>
> The study titled "The Value of Incremental Pharmaceutical
> Innovation: Benefits for Indian Patients and Indian Business"
> underscores the critical role that the protection of incremental
> pharmaceutical innovation must have in ensuring the development of
> new drug products that meet the needs of Indian patients.
>
>
> The Synergies Summit will be attended among others by Indian
> Commerce and Industry Minister Anand Sharma, US Secretary of State
> Hillary Clinton, Commerce Secretary Gary Locke and US Trade
> Representative Ron Kirk.
>
> Industry titans such as USIBC board chairman Indra K. Nooyi,
> chairman and CEO of PepsiCo; Anil Ambani, chairman and CEO of
> Reliance - ADA Group; Azim Premji, chairman of Wipro; and Sy
> Sternberg, retired chairman and CEO of New York Life Insurance
> Company will also take part.
>
>
> Commissioned by the USIBC and the Coalition for Healthy India (CHI)
> bringing together members of the US and Indian business communities
> supporting improved access to healthcare in India , the report was
> funded by the US Chamber of Commerce's Innovation, Development and
> Employment Alliance and produced by White & Case LLP and Dua
> Consulting.
>
>
> The report reasons that Section 3(d) of India 's Patents Act, which
> prevents incremental pharmaceutical innovations from receiving
> patent protection, inhibits development of safer, more efficacious
> and more useful drugs for Indian patients, USIBC said.
>
>
> Drawing upon studies of the impact of incremental pharmaceutical
> innovations on the economies of developed and developing nations,
> interviews with key stakeholders in the Indian pharmaceutical
> sector, and other methods, the report identifies a broad range of
> potential benefits of incremental pharmaceutical innovation for
> India .
>
>
> Along with USIBC and CHI, David Simmons, president and general
> manager, Established Products Business Unit, Pfizer, will
> participate in the release event Wednesday.
>
>
> http://www.hindu.com/thehindu/holnus/099200906161021.htm
>
--
Asia Russell
Health GAP (Global Access Project)
email: asia@healthgap.org
tel: +1 267 475-2645
http://www.healthgap.org